NCT02545907 · REGISTRY CONDITION SEARCH

A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2021-04-15

This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis. The trial begins with a dose escalation phase, in which the maximum tolerated and recommended dose will be determined. The trial will then open into an expansion phase in which the combination efficacy is assessed.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Dose-Limiting Toxicities as Assessed by Reported Data

→

outcome · POSTED

Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0.

→

outcome · POSTED

Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment.

→

outcome · POSTED

Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment.

→

outcome · POSTED

Time to Amyloidotic Organ Response Based on Reported Data.

→

outcome · POSTED

Number of Deaths at 6 Months Based on Reported Data.

→

outcome · POSTED

Number of Patients Progression-free at 6 Months Based on Reported Data.

→

outcome · POSTED

Maximum Response Determined by Paraprotein and Free Light Chain Assessment.

→

outcome · POSTED

Time to Maximum Response Based on Reported Data.

→

outcome · POSTED

Number of Patients Withdrawing From Treatment Based on Reported Data.

→

outcome · POSTED

Number of Patients Experiencing Dose Delays Based on Reported Data.

→

outcome · POSTED

Compliance Profile of KTD Based on Reported Chemotherapy Compliance Data.

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patients with the following characteristics are eligible for this study: 1. Aged 18 years or greater 2. Diagnosis of systemic AL amyloidosis with: * exclusion of genetic mutations associated with hereditary amyloidosis and immunohistochemical exclusion of AA and TTR amyloidosis as appropriate. * Amyloid related organ dysfunction or organ syndrome 3. Measurable clonal disease 4. Clonal relapse after previous chemotherapy or stem cell transplant OR refractory clonal disease to previous chemotherapy or stem cell transplant 5. Capable of providing written, informed consent and willing to follow study protocol 6. Life expectancy ≥ 6 months 7. ECOG performance status of \<3 8. Platelet count ≥ 50x109/l) 9. Neutrophil count ≥ 1x109/l) 10. Haemoglobin ≥ 8g/dL 11. Bilirubin \<2 times or Alkaline phosphatase \<4 times upper limit of normal. 12. Female participants of child-bearing potential must have a negative pregnancy test prior to treatment and agree to use dual methods of contraception for the duration of the study and for 30 days following completion of study. Male participants must also agree to use a barrier method of contraception for the duration of the study and for 30 days following completion of study if sexually active with a female of child-bearing potential. Participants must comply with the Celgene pregnancy prevention programme for thalidomide Exclusion Criteria: * Patients with the following characteristics are ineligible for this study: 1. Overt symptomatic multiple myeloma 2. Amyloidosis of unknown or non AL type 3. Localised AL amyloidosis (in which amyloid deposits are limited to a typical single organ, for example the bladder or larynx, in association with a clonal proliferative disorder within that organ) 4. Trivial or incidental AL amyloid deposits in the absence of a significant amyloid related organ syndrome (e.g., isolated carpal tunnel syndrome). 5. Refractory to or progressive disease with an IMid and proteasome inhibitor combination 6. Allogeneic stem cell transplantation 7. Solid organ transplantation 8. Severe peripheral or autonomic neuropathy causing significant functional impairment. 9. eGFR \<20ml/min 10. Ejection fraction \< 40% or NYHA class III or IV heart failure or uncontrolled hypertension 11. Pulmonary Hypertension 12. Advanced Mayo stage III disease as defined by hs-Troponin T\>0.07 and NT-proBNP \>700 pMol/L OR NT-proBNP \>1000 pMol/L OR supine SBP \<100 mm of Hg 13. Myocardial infarction in the preceeding 6 months or unstable angina or conduction abnormalities uncontrolled by medication or devices 14. Concurrent active malignancies, except surgically removed basal cell carcinoma of the skin or other in situ carcinomas 15. Pregnant, lactating or unwilling to use adequate contraception 16. Systemic infection unless specific anti-infective therapy is employed. 17. Known or suspected HIV infection 18. Contraindication to any of the required concomitant drugs or supportive treatments. Any other clinically significant medical disease or condition or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a participant's ability to give informed consent 19. Previous experimental agents or approved anti-tumour treatment within 3 months before the date of registration 20. Known allergies to the IMPs
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be: * Level -1 - 27mg/m2 * Level 0 - 36mg/m2 * Level 1 - 45mg/m2 * Level 2 - 56mg/m2 Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above.
intervention Names
Drug: Carfilzomib
Drug: Thalidomide
Drug: Dexamethasone
label
KTD treatment
type
EXPERIMENTAL

interventions

arm Group Labels
KTD treatment
description
Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
name
Carfilzomib
other Names
Kyprolis
type
DRUG
arm Group Labels
KTD treatment
description
50mg capsule.
name
Thalidomide
other Names
Thalidomide Celgene
type
DRUG
arm Group Labels
KTD treatment
description
2mg tablet.
name
Dexamethasone
other Names
Decadron
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 10
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Dose-Limiting Toxicities (Dose escalation phase), between the time of receiving the first registered dose of carfilzomib in cycle 1 and day 1 cycle 2, in order to establish the Maximum Tolerated Dose (MTD) of carfilzomib in combination with thalidomide and dexamethasone, will be assessed based on reported data. The number of reported dose limiting toxicities will be reported.
measure
Number of Participants With Dose-Limiting Toxicities as Assessed by Reported Data
time Frame
After 1 cycle of treatment; to be completed within 1 year.
description
The percentage of patients treated who experience any grade 3 or 4 toxicity as assessed by CTCAE v4.0 throughout all treatment cycles will be assessed based on reported data.
measure
Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0.
time Frame
Between informed consent provided and 30 days post last trial treatment administration, up to 7 months

secondary Outcomes

description
Participant clonal response rate within 3 months, at 3 months, within 6 months and at 6 months will be assessed. The percentage of participants who achieve at least a partial response will be reported. Clonal response is defined as: CR: Negative immunofixation of serum and urine (serum alone in anuric patients) AND normal FLC concentration and kappa/lambda FLC ratio (FLC ratio alone in renal failure) AND ≤5% plasma cells in bone marrow without clonality by immunohistochemistry or immunofluorescencea VGPR: \>90% reduction in serum paraprotein or abnormal component of FLC or dFLC over the starting value or dFLC \<40mg/L PR: ≥50% decrease in aberrant FLC concentration or dFLC (or ≥50% decrease in dFLC if renal failure) or serum paraprotein but not fulfilling criteria for CR or VGPR MR: \>25% but \<50% decrease in aberrant FLC or dFLC or paraprotein NR: Not meeting FLC criteria for CR, PR or MR
measure
Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment.
time Frame
Within 3 months, at 3 months, within 6 months and at 6 months
description
Amyloidotic organ response rate is assessed using the following criteria: Heart - Interventricular septal thickness decreased by 2 mm or 10% improvement in ejection fraction or a 30% and 35 pMol/L reduction in NT-ProBNP (only applicable if there is no change or \<25% improvement in renal function) or significant improvement in lateral wall TDI S wave and E/E' ratio Kidney - 50% decrease (at least 0.5 g/day) in 24-hr urinary protein loss (urine protein must be\>0.5 g/day pretreatment) without fall in creatinine clearance of ≥25% from baseline Liver - 50% decrease in abnormal alkaline phosphatase value or a decrease in liver size radiographically by at least 2 cm Nerve - Improvement in electromyogram nerve conduction velocity Soft tissue - Definite clinical and/or radiographic improvement with associated functional improvement in affected tissue. The percentage of patients who achieve organ response within 3 and 6 months of trial registration will be reported.
measure
Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment.
time Frame
Within 3 months and 6 months
description
The time to amyloidotic organ response (as outlined above) will be assessed based on reported data. The number of months this takes will be reported.
measure
Time to Amyloidotic Organ Response Based on Reported Data.
time Frame
Within 6 months
description
The number of deaths at 6 months will be assessed and reported based on reported data.
measure
Number of Deaths at 6 Months Based on Reported Data.
time Frame
6 months
description
The number of patients who are progression-free at 6 months will be assessed based on reported data. Patients who are progression-free will have not had an haematological relapse or organ progression. Haematological relapse is defined as: From CR: Increase in the aberrant serum free light chain concentration to outside the normal range and by a factor of ≥2 from that at the time of CR or re-appearance of the original paraprotein From PR or VGPR: Increase in the aberrant free light chain concentration by a factor of ≥2 from that at the time of PR (≥50% change in ratio away from normal in patients with renal failure) or doubling of the serum paraprotein level (if starting \>5g/L) or doubling and increase of serum paraprotein to \>5g/L (if starting \<5g/L) Organ progression is defined, by organ, as: Heart: Interventricular septal thickness increased by \>2 mm compared with baseline or 20% decline in ejection fraction Kidney: 50% increase (at least 1 g/day) in 24-hr urinary
measure
Number of Patients Progression-free at 6 Months Based on Reported Data.
time Frame
6 months
description
The maximum response to therapy will be determined by assessing the best reported response for each participant. Maximum response will be determined based on free light chain and paraprotein assessments by the National Amyloidosis Centre. The data will be reported using the response rates observed (complete, very good partial, partial, no response).
measure
Maximum Response Determined by Paraprotein and Free Light Chain Assessment.
time Frame
Within 6 months
description
The time to maximum response to treatment will be assessed by determining the time required for each participant to achieve maximum response (defined above), and will be presented on Kaplan-Meier curves. The number of months taken to achieve this maximum response will be reported. Time to maximum response was analysed overall only, and not by arm due the small sample size.
measure
Time to Maximum Response Based on Reported Data.
time Frame
Within 6 months
description
The number of patients withdrawing from treatment will be assessed based on reported data.
measure
Number of Patients Withdrawing From Treatment Based on Reported Data.
time Frame
Within 6 months
description
The number of patients experiencing dose delays will be assessed based on reported data.
measure
Number of Patients Experiencing Dose Delays Based on Reported Data.
time Frame
Within 6 months
description
The compliant profile of participants to KTD will be assessed by determining the number of missed doses from recorded data. Participants will be regarded as compliant if participants have missed no more than 14 days of thalidomide, 2 days of dexamethasone, and 1 dose of carfilzomib per cycle. Compliance will be reported in terms of the number of participants who were compliant.
measure
Compliance Profile of KTD Based on Reported Chemotherapy Compliance Data.
time Frame
Within 6 months

Full study description

brief Summary: This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis. The trial begins with a dose escalation phase, in which the maximum tolerated and recommended dose will be determined. The trial will then open into an expansion phase in which the combination efficacy is assessed.
detailed Description: Amyloidosis is a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively disrupt tissue structure and impair function. The treatment of systemic AL amyloidosis has evolved to a risk adapted approach based on the end organ damage, particularly cardiac involvement, and the functional status of the patient. Intensive therapies like high dose melphalan followed by an autologous stem cell transplant are considered for patients with limited organ involvement, younger age and excellent functional status. The majority of patients with AL amyloidosis, however, will not be candidates for ASCT and are generally treated with combination chemotherapy. This therapy may include bortezomib, a proteasome inhibitor which is particularly effective in AL amyloidosis but which may have a severe side-effect profile. Carfilzomib is specific for the chymotrypsin-like active site of the 20S proteasome, is structurally and mechanistically distinct from bortezomib, and has demonstrated less reactivity against non-proteasomal proteases when compared to bortezomib. It also appears to be better tolerated. However, information regarding the use of carfilzomib in the treatment of AL amyloidosis is limited. In the dose escalation phase of this study, a minimum of 6 (3 at dose level 0 and 3 at dose level -1)and a maximum of 18 (6 at dose level 0, 1, and 2) patients will recruited in a 3+3 design with cohorts of between 3 and 6 patients, in order to determine maximum tolerated dose and recommended dose. At the recommended dose level identified, a further 20 (minimum) patients will be recruited to further assess safety and toxicities at the RD.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-977b70552fc409b6584e
requested nct id
NCT02545907
primary nct id
NCT02545907
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
cdcf35b4733a15a5c554106f2b0b898d35994129a95f260f8640d4d6dc80f985
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-977b70552fc409b6584e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02545907
occurrences
context exact
NCT02545907
end
11
exact text
NCT02545907
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/648/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
e3b9234c6d9f4792252c46c145d37214f32cd060c35c9787030fc1663de25932
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice